Relapsed/refractory Diffuse Large B-Cell Lymphoma has emerging NIH research funding with 1 grant totaling $992K.
1 new grant started in the last 12 months.
Cross-referencing NIH grants against published research and clinical trials to identify funding-evidence gaps for Relapsed/refractory Diffuse Large B-Cell Lymphoma. Strongest funded area: Gene Therapy / Cell Therapy. Largest gap: Clinical Research.
25 clinical trials registered but no NIH-funded clinical or translational research grants found for relapsed/refractory diffuse large B-cell lymphoma. Trials may be industry-sponsored or funded through non-NIH sources.
7 publications in Diagnostic / Biomarker but no NIH-funded grants found in Biomarker / Diagnostics for relapsed/refractory diffuse large B-cell lymphoma. Existing research activity suggests this may be a viable area for grant applications.
5 publications in Case Report / Case Series but no NIH-funded grants found in Epidemiology / Natural History for relapsed/refractory diffuse large B-cell lymphoma. Existing research activity suggests this may be a viable area for grant applications.
53 publications in Clinical Trial Publication but no NIH-funded grants found in Clinical Research for relapsed/refractory diffuse large B-cell lymphoma. Existing research activity suggests this may be a viable area for grant applications.
11 publications in Basic Science / Preclinical but no NIH-funded grants found in Basic Science for relapsed/refractory diffuse large B-cell lymphoma. Existing research activity suggests this may be a viable area for grant applications.
Track funding opportunities for Relapsed/refractory Diffuse Large B-Cell Lymphoma.
Follow this disease to be notified about new NIH grants and funding changes.
Already have an account? Sign in to manage your watchlists.